Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
about
Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overloadPrognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand?Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment.A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosisEfficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation
P2860
Q30240070-3F9C4E1F-FE5D-4BA1-B6E9-74D198AF60BEQ33905984-C21F3FC0-A121-4CB6-A2A2-5FC73D1A31CAQ35185407-063C4DC2-E04C-4398-8F73-FA8BC7AF57D3Q37389675-354893D2-8DB1-477D-A1DB-0DAD0FAD715BQ38083570-20BA54BC-0757-4170-BA24-934567415ED7Q38101043-27D70DD8-C8BC-4875-B512-E0BE1315F78AQ38783289-C40CA80E-17A6-4C12-90B5-576889AE7476Q42013707-68F83146-A7FC-49B3-9B1F-C738915B5095Q42266529-68E33166-F7C9-4DAC-AE04-2F70F2CA83DAQ47203177-D47AF6C7-AA82-4C75-9546-8B1C3C0D4AAFQ57108843-6080C6E7-9B11-48A4-A680-525451DB4653Q57515058-640FE553-05F6-4EB7-9A15-A55D912A6321
P2860
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Efficacy and safety of oral de ...... ll transplantation (alloHSCT).
@en
Efficacy and safety of oral de ...... etic stem cell transplantation
@nl
type
label
Efficacy and safety of oral de ...... ll transplantation (alloHSCT).
@en
Efficacy and safety of oral de ...... etic stem cell transplantation
@nl
prefLabel
Efficacy and safety of oral de ...... ll transplantation (alloHSCT).
@en
Efficacy and safety of oral de ...... etic stem cell transplantation
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of oral de ...... ell transplantation (alloHSCT)
@en
P2093
Ahmet Ozturk
Bulent Eser
Cigdem Pala
Elmas Uzer
Fatih Kurnaz
Kemal Deniz
Sami Bahcebasi
Serdar Sivgin
P2860
P304
P356
10.1007/S00277-011-1358-1
P577
2011-11-04T00:00:00Z